Flurazepam Hydrochloride

CHEMBL3989724 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

460.8 g/mol

LogP

—

Phase

4

A hydrochloride salt form of flurazepam, a benzodiazepine used to treat short-term insomnia by enhancing inhibitory signaling in the brain to promote sleep. This salt form improves the drug's solubility for oral administration. Patients should be aware of the risk of tolerance, dependence, and next-day sedation.

Peso molecular

460,8000 g/mol

TPSA

35,90 Å²

Áreas terapéuticas

Schizophrenia Generalized Anxiety Disorder

Mecanismo de acción

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl

InChI

InChI=1S/C21H23ClFN3O.2ClH/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23;;/h5-10,13H,3-4,11-12,14H2,1-2H3;2*1H

Molecular Formula

C21H25Cl3FN3O

HBD / HBA

2 / 4

Enlaces Rotables

6

Átomos Pesados

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A hydrochloride salt form of flurazepam, a benzodiazepine used to treat short-term insomnia by enhancing inhibitory signaling in the brain to promote sleep. This salt form improves the drug's solubility for oral administration. Patients should be aware of the risk of tolerance, dependence, and next-day sedation.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Flurazepam Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989724. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 14434. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Flurazepam Hydrochloride en PillFYI

Estructura

Datos Rápidos

Fórmula: C21H25Cl3FN3O
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.